Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Clinuvel Pharmaceuticals ( (AU:CUV) ) has issued an announcement.
Clinuvel Pharmaceuticals has successfully recruited over 200 patients for its Phase III trial (CUV105) of SCENESSE® in treating vitiligo, with results expected in the second half of 2026. The trial, conducted across North America, Africa, and Europe, aims to evaluate the efficacy of SCENESSE® as a systemic repigmentation therapy in combination with narrowband ultraviolet B phototherapy. Initial clinical observations have been positive, and the company is preparing for further regulatory discussions and a subsequent trial, CUV107, to expand its market presence.
More about Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals operates in the pharmaceutical industry, focusing on developing treatments for skin disorders. Their primary product, SCENESSE® (afamelanotide), is aimed at treating conditions like vitiligo, with a market focus on systemic repigmentation therapies for patients with darker skin types.
Average Trading Volume: 176,459
Technical Sentiment Signal: Sell
Current Market Cap: A$580.9M
For an in-depth examination of CUV stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue